Open AccessIntraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer
Author(s) -
Ann L. Miller,
Caitlin D Lemke-Miltner,
Sue Blackwell,
Ann Tomanek-Chalkley,
Katherine N Gibson-Corely,
Kristen L. Coleman,
George J. Weiner,
Carlos Chan
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-08591-7
Subject(s) - medicine , ex vivo , tumor microenvironment , immune system , cancer research , peritoneal cavity , immunotherapy , chemokine , flow cytometry , in vivo , surgical oncology , cd8 , immunology , biology , microbiology and biotechnology , anatomy
The treatment options for patients with peritoneal carcinomatosis (PC) of gastrointestinal and pancreaticobiliary origins are limited. The virus-like particle, CMP-001, composed of the Qβ bacteriophage capsid protein encapsulating a CpG-A oligodeoxynucleotide, activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.